Analysis of chromosomal instability in pulmonary or liver metastases and matched primary hepatocellular carcinoma after orthotopic liver transplantation

International Journal of Cancer

Volumn 104, Issue 6, 2003, Pages 745-751

  Gross Goupil, Marine ^a   Riou, Philippe ^a   Emile, Jean François ^a   Saffroy, Raphaël ^a   Azoulay, Daniel ^b   Lacherade, Isabelle ^a   Receveur, Aline ^a   Platier Tonneau, Dominique ^c   Castaing, Denis ^b   Debuire, Brigitte ^a   Lemoine, Antoinette ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c CNRS   (France)

Author keywords

catenin; Hepatocellular carcinoma; Loss of heterozygosity; Metastasis; Microsatellite instability; P53

Indexed keywords

BETA CATENIN; DNA; PROTEIN P53;

ARTICLE; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CYTOGENETICS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TRANSPLANTATION; LUNG METASTASIS; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; ALLELES; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CHROMOSOMES; CYTOSKELETAL PROTEINS; DNA PRIMERS; DNA, NEOPLASM; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037431508     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11017     Document Type: Article

References (66)

1. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-51.
2. Franco D, Capusotti L, Smadja C, Bouzari H, Meakins J, Kemeny F. Resection of hepatocellular carcinomas: results in 72 European patients with cirrhosis. Gastroenterology 1990;98:733-38.
3. Mazaferro V, Regalia E. Doci R, Andreola S, Pulvirenti A, Bozzetti F. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-99.
4. Nagasue N, Kohno H, Chanf YC, Taniura H, Yamanoi A, Uchida M. Liver resection for hepatocellular carcinoma. Ann Surg 1993;217: 375-84.
5. Ringe B, Pinchlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World Surg 1991;15:270-85.
6. Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995;108:768-75.
7. Calvet X, Bruix J, Gines P, Bru C, Sole M, Vilana R. Prognostic factors of hepatocellular carcinoma in the West: a multivariate analysis in 206 patients. Hepatology 1990;12:753-60.
8. Ng IO, Lai EC, Fan ST, Ng MM, So MK. Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients. Cancer 1995;76:2443-48.
9. Bourdon JC, D'Errico A, Paterlini P, Grigioni W, May E, Debuire B. p53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology 1995;108: 1176-82.
10. Bressac B, Kew M, Wands J, Osturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. Nature 1991;350:429-31.
11. Challen C, Lunec J, Warren W, Collier J, Bassendine MF. Analysis of the p53 tumor suppressor gene in hepatocellular carcinoma from Britain. Hepatology 1992;16:1362-6.
12. Debuire B, Paterlini P, Pontisso P, Basso G, May E. Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene 1993;8:2303-6.
13. Kress S, Jahn UR, Buchmann A, Bannasch P, Schwarz M. p53 mutations in human hepatocellular carcinomas from Germany. Cancer Res 1992;52:3220-3.
14. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95:8847-51.
15. Legoix P, Bluteau O, Bayer J, Perret C, Balabaud C, Belghiti J. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999;18:4044-6.
16. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120:1763-73.
17. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11:447-9.
18. Chaubert P, Gayer R. Zimmermann A, Fontolliet C, Stamm B, Bosman F. Germ-line mutations of the p161NK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology 1997; 25:1376-81.
19. Feo F, Pascale RM, Simile MM, De Miglio MR, Muroni MR, Calvisi D. Genetic alterations in liver carcinogenesis: implications for new preventive and therapeutic strategies. Crit Rev Oncog 2000;11:19-62.
20. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185-200.
21. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis 1999;19:235-42.
22. Okuda T, Hirohashi K, Kinoshita H, Wakasa K, Sakurai M. Characteristic histologic features of human hepatocellular carcinoma with mutant p53 protein. World J Surg 1996;20:215-20.
23. Honda K, Sbisa E, Tullo A, Papeo PA, Saccone C, Poole S, Pignatelli M, Mitry RR, Ding S, Isla A, Davies A, Habib NA. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer 1998; 77:776-82.
24. Salvucci M, Lemoine A, Saffroy R, Azoulay D, Lepere B, Gaillard S. Microsatellite instability in European hepatocellular carcinoma. Oncogene 1999:18:181-7.
25. Saffroy R, Lelong JC, Azoulay D, Salvucci M, Reynes M, Bismuth H, Debuire B, Lemoine A. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 1999;79:604-10.
26. Mirabelli-Primdahl L, Gryfe R, Kim H, Millar A, Luceri C, Dale D. &-bgr;-Catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999;59:3346-51.
27. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995;91:41-7.
28. Chen YJ, Yeh SH, Chen JT, Wu CC, Hsu MT, Tsai SF. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000;119:431-40.
29. Boige V, Laurent-Puig P, Fouchet P, Flejou JF, Monges G, Bedossa P. Concerted nonsystenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. Cancer Res 1997;57:1986-90.
30. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997; 14:2927-33.
31. Piao Z, Park C, Kim JJ, Kim H. Deletion mapping of chromosome 16q in hepatocellular carcinoma. Br J Cancer 1999;80:850-4.
32. Yeh SH, Chen PJ, Lai MY, Chen DS. Allelic loss on chromosomes 4q and 16q in hepatocellular carcinoma: association with elevated α-fetoprotein production. Gastroenterology 1996;110:184-92.
33. Macdonald GA, Greenson JK, Saito K, Cherian SP, Appelman HD, Boland CR. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology 1998;28:90-7.
34. Sheu JC, Lin YW, Chou HC, Huang GT, Lee HS, Lin YH. Loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in Taiwan. Br J Cancer 1999:80:468-76.
35. Yamamoto H, Itoh F, Fukushima H, Kaneto H, Sasaki S, Ohmura T. Infrequent widespread microsatellite instability in hepatocellular carcinomas. Int J Oncol 2000;16:543-7.
36. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Microsatellite instability associated with hepatocarcinogenesis. J Hepatol 1999;431:529-36.
37. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis - a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000;32:970-99.
38. Saeki A, Tamura S, Ito N, Kiso S, Matsuda Y, Yabuuchi I. Lack of frameshift mutations at coding mononucleotide repeats in hepatocellular carcinoma in Japanese patients. Cancer 2000;88:1025-9.
39. Piao Z, Kim H, Malkhosyan S, Park C. Frequent chromosomal instability but no microsatellite instability in hepatocellular carcinomas. Int J Oncol 2000;17:507-12
40. Nozaki I, Ohashi R, Matsubara N, Hirai R, Andou A, Miyazaki M. Microsatellite instability correlates with normal expression of cyclin E in hepatocellular carcinomas. Int J Oncol 2001;18:1265-9.
41. Takagi K, Esumi M, Takano S, Iwai S. Replication error frequencies in primary hepatocellular carcinoma: a comparison of solitary primary versus multiple primary cancers. Liver 1998;18:272-6.
42. Salvucci M, Lemoine A, Azoulay D, Sebagh M, Bismuth H, Reynes M. Frequent microsatellite instability in post hepatitis B viral cirrhosis. Oncogene 1996;13:2681-5.
43. Brentnall TA, Chen R, Lee JG, Kimmey MB, Bronner MP, Haggitt RC. Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res 1995;55: 4264-7.
44. Brentnall TA, Crispin DA. Bronner MP, Cherian SP, Hueffed M, Rabinovitch PS. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res 1996;56: 1237-40.
45. Roncalli M, Bianchi P, Grimaldi GC, Ricci D, Laghi L, Maggioni M. Fractional allelic loss in non-end-stage cirrhosis: correlations with hepatocellular carcinoma development during follow-up. Hepatology 2000;31:846-50.
46. Kawai H, Suda T, Aoyagi Y, Isokawa O, Mita Y, Waguri N. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology 2000;31:1246-50
47. Chen PJ, Chen DS, Lai MY, Chang MH, Huang GT, Yang PM. Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology 1989;96:527-9
48. Hsu HC. Chiou TJ, Chen JY, Lee CS, Lee PH, Peng SY. Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology 1991;13:923-8.
49. Sheu JC, Huang GT, Chou HC, Lee PH, Wang JT, Lee HS. Multiple hepatocellular carcinomas at the early stage have different clonality. Gastroenterology 1993;105:1471-6.
50. Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Poutanen M, Vihko R, Vihko P. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res 1997;57:3356-9.
51. Pan Y, Matsuyama H, Wang N, Yoshihiro S, Haggarth L, Li C, Tribukait B, Ekman P, Bergerheim US. Chromosome 16q24 deletion and decreased E-cadherin expression: possible association with metastatic potential in prostate cancer. Prostate 1998;36:31-8.
52. Grundy RG, Pritchard J, Scambler P, Cowell JK. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. Br J Cancer 1998;78:1181-7.
53. Shearer PD, Valentine MB. Grundy P, DeCou JM, Banavali SD, Komuro H, Green DM. Beckwith JB, Look AT. Hemizygous deletions of chromosome band 16q24 in Wilms tumor: detection by fluorescence in situ hybridization. Cancer Genet Cytogenet 1999; 115: 100-5.
54. Mason JE, Goodfellow PJ, Grundy PE, Skinner MA. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor. J Pediatr Surg 2000;35:891-7.
55. Skotnicka-Klonowicz G, Rieske P, Bartkowiak J, Szymik-Kantorowicz S, Daszkiewicz P, Debiec-Rychter M. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance. Eur J Surg Oncol 2000;26:61-6.
56. Chen T, Sahin A, Aldaz CM. Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res 1996;56:5605-9.
57. Cleton-Jansen AM, Callen DF, Seshadri R, Goldup S, McCallum B, Crawford J, Powell JA, Settasatian C, van Beerendonk H, Moerland EW, Smit VT, Harris WH, et al. Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Res 2001;6:1171-7.
58. Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI, Shridhar V. Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. Int J Oncol 1999;15:715-20.
59. Suzuki S, Moore DH 2nd. Ginzinger DG, Godfrey TE. Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, et al. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 2000; 60:5382-5.
60. Launonen V, Mannermaa A, Stenback F, Kosma VM, Puistola U, Huusko P, Anttila M, Bloigu R, Saarikoski S, Kauppila A, Winqvist R. Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables. Cancer Genet Cytogenet 2000;122:49-54.
61. Grundy RG, Pritchard J, Scambler P, Cowell JK. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. Br J Cancer 1998;78:1181-7.
62. Mashimo T, Watabe M, Cuthbert AP, Newbold RF, Newbold RF, Rinker-Schaeffer CW. Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells. Cancer Res 1998; 58:4572-6.
63. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60:2140-5.
64. Saffroy R, Rioun P, Soler G, Azoulay D, Emile JF, Debuire B, Lemoine A. Analysis of alterations of WFDC1, a new putative tumour suppressor gene, in hepatocellular carcinoma. Eur J Hum Genet 2002;10:239-44.
65. Riou P, Saffroy R, Comoy J, Gross-Goupil M, Thiery JP, Emile JF, Azoulay D, Piatier-Tonneau D, Lemoine A, Debuire B. Investigation in liver tissues and cell lines of the transcription of 13 genes mapping to the 16q24 region that are frequently deleted in hepatocellular carcinoma. Clin Cancer Res 2002;8:3178-86.
66. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T. AXINI mutations in hepatocellular carcinoma, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000;24:245-50.